Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
4.960
+0.190 (3.98%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Unicycive Therapeutics Employees
As of December 31, 2025, Unicycive Therapeutics had 22 total employees, including 21 full-time and 1 part-time employees. The number of employees decreased by 1 or -4.35% compared to the previous year.
Employees
22
Change (1Y)
-1
Growth (1Y)
-4.35%
Revenue / Employee
n/a
Profits / Employee
-$1,601,045
Market Cap
138.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | -1 | -4.35% | 21 | 1 |
| Dec 31, 2024 | 23 | 9 | 64.29% | 22 | 1 |
| Dec 31, 2023 | 14 | 2 | 16.67% | 14 | 0 |
| Dec 31, 2022 | 12 | 3 | 33.33% | 12 | 0 |
| Dec 31, 2021 | 9 | 8 | 800.00% | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Inovio Pharmaceuticals | 112 |
| Immunic | 100 |
| Caribou Biosciences | 97 |
| enGene Therapeutics | 82 |
| Neumora Therapeutics | 63 |
| Milestone Pharmaceuticals | 38 |
| TuHURA Biosciences | 22 |
UNCY News
- 7 days ago - Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies - Newsfile Corp
- 7 days ago - Unicycive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 13 days ago - Unicycive Therapeutics Slides: Corporate presentation - Filings
- 21 days ago - Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics price target raised to $15 from $13 at Benchmark - TheFly
- 5 weeks ago - Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c) - TheFly
- 5 weeks ago - Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley - TheFly
- 5 weeks ago - Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim - TheFly